Activated protein C concentrate treatment for skin necrosis under warfarin treatment in severe genetic protein C deficiency combined with prothrombin mutation and factor V Leiden.
Rosenzweig
Naomi
N
Cheba-Medical -Center, Tel-Hashomer Ramat-Gan, Israel 52621.
Strauss
Tzipora
T
Rubinstein
Marina
M
Paret
Gideon
G
Kenet
Gili
G
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects / Q000235:genetics; D016913:Blood Component Transfusion; D002648:Child; D017984:Enoxaparin / Q000627:therapeutic use; D005165:Factor V / Q000235:genetics*; D006801:Humans; D008297:Male; D009154:Mutation; D011486:Protein C / Q000627:therapeutic use*; D020151:Protein C Deficiency / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D011516:Prothrombin / Q000235:genetics*; D055665:Purpura Fulminans / Q000188:drug therapy* / Q000235:genetics; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
D000925:Anticoagulants; D017984:Enoxaparin; D011486:Protein C; D011994:Recombinant Proteins; C095381:factor V Leiden; D014859:Warfarin; D005165:Factor V; D011516:Prothrombin; C421124:drotrecogin alfa activated